Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Thu, 18-Dec 8:00 AM ET)
Market Chameleon (Mon, 29-Sep 3:07 AM ET)
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Larimar Therapeutics trades on the NASDAQ stock market under the symbol LRMR.
As of February 13, 2026, LRMR stock price was flat at $3.21 with 217,862 million shares trading.
LRMR has a beta of 1.92, meaning it tends to be more sensitive to market movements. LRMR has a correlation of 0.16 to the broad based SPY ETF.
LRMR has a market cap of $266.72 million. This is considered a Small Cap stock.
In the last 3 years, LRMR traded as high as $13.68 and as low as $1.61.
The top ETF exchange traded funds that LRMR belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
LRMR has underperformed the market in the last year with a price return of -0.6% while the SPY ETF gained +14.7%. LRMR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.7% and -10.1%, respectively, while the SPY returned +0.5% and -1.3%, respectively.
LRMR support price is $3.05 and resistance is $3.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LRMR shares will trade within this expected range on the day.
